| [1] |
Huang L, Xiao Y, Yang L, et al. The development for emerging biomarkers of lymphangioleiomyomatosis[J]. Orphanet J Rare Dis, 2024, 19(1):445.
|
| [2] |
McCarthy C, Gupta N, Johnson SR, et al. Lymphangioleiomyomatosis: Pathogenesis, clinical features, diagnosis, and management[J]. Lancet Respir Med, 2021, 9(11):1313-1327.
doi: 10.1016/S2213-2600(21)00228-9
pmid: 34461049
|
| [3] |
Kimura Y, Jo T, Hashimoto Y, et al. Epidemiology of patients with lymphangioleiomyomatosis: A descriptive study using the national database of health insurance claims and specific health checkups of Japan[J]. Respir Investig, 2024, 62(3):494-502.
|
| [4] |
Rebaine Y, Nasser M, Girerd B, et al. Tuberous sclerosis complex for the pulmonologist[J]. Eur Respir Rev, 2021, 30(161):200348.
|
| [5] |
Evans JF, McCormack FX, Sonenberg N, et al. Lost in translation: A neglected mTOR target for lymphangioleiomyomatosis[J]. Eur Respir Rev, 2023, 32(169):230100.
|
| [6] |
Brakemeier S, Grohé C, Bachmann F, et al. Sporadic lymphangioleiomyomatosis (sLAM) and tuberous sclerosis complex (TSC)-pulmonary manifestations[J]. Pneumologie, 2017, 71(2):86-95.
doi: 10.1055/s-0042-111522
pmid: 27585353
|
| [7] |
Lu Y, Liu X, Zhang E, et al. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells[J]. PLoS One, 2020, 15(2):e0228894.
|
| [8] |
Kundu N, Holz MK. Lymphangioleiomyomatosis: A metastatic lung disease[J]. Am J Physiol Cell Physiol, 2023, 324(2):C320-C326.
|
| [9] |
Xu KF, Xu W, Liu S, et al. Lymphangioleiomyomatosis[J]. Semin Respir Crit Care Med, 2020, 41(2):256-268.
|
| [10] |
Tai J, Liu S, Yan X, et al. Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis[J]. Orphanet J Rare Dis, 2024, 19(1):236.
doi: 10.1186/s13023-024-03239-1
pmid: 38877584
|
| [11] |
Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: High-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline[J]. Am J Respir Crit Care Med, 2017, 196(10):1337-1348.
|
| [12] |
Xu W, Yang C, Cheng C, et al. Determinants of progression and mortality in lymphangioleiomyomatosis[J]. Chest, 2023, 164(1):137-148.
|
| [13] |
Amaral AF, de Oliveira MR, Dias OM, et al. Concentration of serum vascular endothelial growth factor (VEGF-D) and its correlation with functional and clinical parameters in patients with lymphangioleiomyomatosis from a Brazilian Reference Center[J]. Lung, 2019, 197(2):139-146.
doi: 10.1007/s00408-018-00191-3
pmid: 30623243
|
| [14] |
Hirose M, Matsumuro A, Arai T, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis[J]. PLoS One, 2019, 14(2):e0212776.
|
| [15] |
Martins B, Fernandes R. Disturbed matrix metalloproteinases activity in age-related macular degeneration[J]. Adv Exp Med Biol, 2023, 1415:21-26.
doi: 10.1007/978-3-031-27681-1_4
pmid: 37440009
|
| [16] |
Terraneo S, Lesma E, Ancona S, et al. Exploring the role of matrix metalloproteinases as biomarkers in sporadic lymphangioleiomyomatosis and tuberous sclerosis complex. A pilot study[J]. Front Med (Lausanne), 2021, 8:605909.
|
| [17] |
Ancona S, Orpianesi E, Bernardelli C, et al. Differential modulation of matrix metalloproteinases-2 and -7 in LAM/TSC cells[J]. Biomedicines, 2021, 9(12):1760.
|
| [18] |
Bradding P, Pejler G. The controversial role of mast cells in fibrosis[J]. Immunol Rev, 2018, 282(1):198-231.
doi: 10.1111/imr.12626
pmid: 29431218
|
| [19] |
Babaei-Jadidi R, Dongre A, Miller S, et al. Mast-cell tryptase release contributes to disease progression in lymphangioleiomyomatosis[J]. Am J Respir Crit Care Med, 2021, 204(4):431-444.
|
| [20] |
Inoue C, Miki Y, Saito-Koyama R, et al. Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors[J]. Pathol Res Pract, 2022, 230:153758.
|
| [21] |
Liu X, Xu Y, Wu X, et al. Soluble immune-related proteins as new candidate serum biomarkers for the diagnosis and progression of lymphangioleiomyomatosis[J]. Front Immunol, 2022, 13:844914.
|
| [22] |
Esposito AJ, Imani J, Shrestha S, et al. Lymphangioleiomyomatosis: Circulating levels of FGF23 and pulmonary diffusion[J]. J Bras Pneumol, 2023, 49(2):e20220356.
|
| [23] |
Wang YY, Zou LP, Xu KF, et al. Long-term safety and influence on growth in patients receiving sirolimus: A pooled analysis[J]. Orphanet J Rare Dis, 2024, 19(1):299.
|
| [24] |
Bee J, Fuller S, Miller S, et al. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: A prospective national cohort study[J]. Thorax, 2018, 73(4):369-375.
doi: 10.1136/thoraxjnl-2017-210872
pmid: 28993539
|
| [25] |
Moir LM. Lymphangioleiomyomatosis: Current understanding and potential treatments[J]. Pharmacol Ther, 2016, 158:114-124.
|
| [26] |
Koc-Gunel S, Liu EC, Gautam LK, et al. Targeting fibroblast-endothelial interactions in LAM pathogenesis: 3D spheroid and spatial transcriptomic insights for therapeutic innovation[J]. bioRxiv[Preprint], 2024:2023.06.12.544372.
|
| [27] |
Pimenta SP, Baldi BG, Kairalla RA, et al. Doxycycline use in patients with lymphangioleiomyomatosis: Biomarkers and pulmonary function response[J]. J Bras Pneumol, 2013, 39(1):5-15.
doi: S1806-37132013000100002
pmid: 23503480
|
| [28] |
Alayev A, Sun Y, Snyder RB, et al. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells[J]. Cell Cycle, 2014, 13(3):371-382.
doi: 10.4161/cc.27355
pmid: 24304514
|
| [29] |
Alayev A, Berger SM, Holz MK. Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation[J]. Ann N Y Acad Sci, 2015, 1348(1):116-123.
|
| [30] |
Blankenstein T, Coulie PG, Gilboa E, et al. The determinants of tumour immunogenicity[J]. Nat Rev Cancer, 2012, 12(4):307-313.
doi: 10.1038/nrc3246
pmid: 22378190
|
| [31] |
Minor BMN, LeMoine D, Seger C, et al. Estradiol augments tumor-induced neutrophil production to promote tumor cell actions in lymphangioleiomyomatosis models[J]. Endocrinology, 2023, 164(6):bqad061.
|
| [32] |
Thomas A, Sumughan S, Dellacecca ER, et al. Benign tumors in TSC are amenable to treatment by GD3 CAR T cells in mice[J]. JCI Insight, 2021, 6(22):e152014.
|
| [33] |
Bernardelli C, Caretti A, Lesma E. Dysregulated lipid metabolism in lymphangioleiomyomatosis pathogenesis as a paradigm of chronic lung diseases[J]. Front Med (Lausanne), 2023, 10:1124008.
|
| [34] |
Krymskaya VP, Courtwright AM, Fleck V, et al. A phase II clinical trial of the safety of simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex[J]. Respir Med, 2020, 163:105898.
|
| [35] |
Fletke KJ, Taylor N, Shah N. Management of a rare case of lymphangioleiomyomatosis complicated by recurrent pneumothorax[J]. BMJ Case Rep, 2024, 17(9):e260369.
|
| [36] |
Warrior K, Dilling DF. Lung transplantation for lymphangioleiomyomatosis[J]. J Heart Lung Transplant, 2023, 42(1):40-52.
|
